Hualan Biological

Hualan Biological Engineering Inc., founded in 1992, is a high-tech enterprise and a national innovative pilot enterprise engaged in the research, development, production, and sales of biological products such as blood products, vaccines, and recombinant proteins.

In the field of blood products, the company possesses numerous blood products under the "Hualan" brand, including human serum albumin, intravenous human immunoglobulin, human immunoglobulin, human prothrombin complex, and surgical lyophilized human fibrin sealant. It is one of the enterprises in China's blood product industry with high comprehensive plasma utilization rate, a wide variety of products, and complete specifications.

In the vaccine field, the company has established a relatively large-scale vaccine industrialization platform and emergency research and development system in China, capable of rapidly responding to and effectively addressing emerging infectious diseases. Currently, there are 9 vaccine products on the market, and the company is the first enterprise in China to obtain approval for the production of quadrivalent influenza vaccines.

In the recombinant protein field, the company actively deploys the research and development of monoclonal antibodies. At present, several monoclonal antibody drugs of Hualan have entered the clinical trial stage.

"Gratitude, service, and caring feedback," Hualan Biological has long-term support for welfare institutions, nursing homes, hemophilia patients, and impoverished college students. In the face of sudden major disasters and epidemics, the company actively participates in relief efforts with both drugs and funds, practicing its corporate social responsibility through concrete actions and has been awarded the China Charity Award by the Ministry of Civil Affairs.